|
Home
|
Immunohistochemical and Clinical Characterization of the Basal-like Subtype of Invasive Breast Carcinoma Homepage
|
|
CaseXplorer
|
Treeview CaseXplorer
|
|
Figures
|
Figures from the paper
|
|
WebPortal
|
Stanford Tissue Microarray Consortium Web Portal
|
|
Authors
|
Authors
|
|
|
|
Figures
|
 Figure
1. Gene expression patterns in basal-like tumors and their correlation with immunohistochemistry.
A) The 115 patient/tumor sample dendrogram was taken from the hierarchical clustering analysis presented in
Sorlie et al. 2003 (2); the tumors were grouped using the breast "intrinsic" gene list based upon 50 paired samples.
The BBC are identified in red. The gene expression data for ER, HER2, c-KIT, CK5 and HER1 are shown with red
squares representing the highest average expression, black representing average gene expression and green r
epresenting the lowest below average. B) 21 BBC identified by gene expression profiling were tested and scored
by IHC for CK5/6, HER1, c-KIT, ER and HER2 (0 = negative, 1 = weak and/or focal staining, 2 = strong diffuse
staining), except for HER2, which was scored using a standard (0-3+) scale. ND = not determined. C) Representative
immunostaining results for 4 basal-like tumors and a normal breast
sample for CK5/6 and HER1. Warning: Large file 17MB
|
 Figure 2.
Figure 2. Kaplan-Meier survival curves
based upon basal cytokeratin and HER1
staining. A)Kaplan-Meier disease-specific
survival (DSS) curve for 829 tumours assessed
for cytokeratin 5/6 and cytokeratin
17. B)Kaplan-Meier disease-specific survival
(DSS) curve for 472 lymph node positive breast
cancers assessed for cytokeratin 5/6 and
cytokeratin 17. C)Kaplan-Meier
disease-specific survival (DSS) curve for 210
lymph node negative breastcancers assessed for
cytokeratin 5/6 and cytokeratin 17. D)Kaplan
Meier disease-specific survival (DSS) curve in
609 breast cancers assessed for HER1
immunostaining. |
 Figure 3. Hierarchical cluster analysis of breast carcinoma tissue microarray immunostaining results.
The six markers evaluated in this study (ER, HER1, HER2, c-KIT, CK5/6 and CK17) were scored and used
in a clustering analysis where each row represents a different tumor, and each column represents a
different IHC stain. The analysis shows that the basal-like markers stained similar cases, as indicated
by the very short dendrogram branches linking these markers. |
 Figure 4.
Kaplan Meier disease specific survival (DDS) analysis of breast
carcinoma subtypes defined by ER, HER2, CK5/6
and HER1 immunohistochemistry. Group B (the
basal-like subtype) is defined as negative for
ER, negative for
HER2 and positive for HER1 and/or CK5/6.
Group E (the luminal subtype) are positive for
ER and negative for HER2. Group H (clinically
HER2 3+) are positive for HER2.
|
|
|
